Patents Assigned to Taisho Pharmaceutical Co.
-
Publication number: 20150196476Abstract: Upon attempting to design a pharmaceutical preparation by mixing minoxidil with a general thickening agent during a process for considering a minoxidil-containing composition for an agent for external use in which dripping is inhibited, it was discovered that the pharmaceutical preparation would have sediments or would cloud and that a sufficient viscosity of the pharmaceutical preparation could not be obtained. The minoxidil-containing composition for an agent for external use of the present invention is characterized by containing minoxidil (a), a hydroxypropyl cellulose and hypromellose (b), ethanol (c), and water (d). Said composition is clear and has a good feel upon use, and dripping of the composition is inhibited.Type: ApplicationFiled: July 25, 2013Publication date: July 16, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Tomoko Ida, Saori Ideura
-
Patent number: 9073821Abstract: Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria.Type: GrantFiled: April 20, 2011Date of Patent: July 7, 2015Assignees: TAISHO PHARMACEUTICAL CO., LTD, TOYAMA CHEMICAL CO., LTD.Inventors: Hajime Takashima, Risa Tsuruta, Tetsuya Yabuuchi, Yusuke Oka, Hiroki Urabe, Yoichiro Suga, Masato Takahashi, Fumito Uneuchi, Hironori Kotsubo, Muneo Shoji, Yasuko Kawaguchi
-
Publication number: 20150183768Abstract: A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity.Type: ApplicationFiled: June 13, 2013Publication date: July 2, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Aya Futamura, Yuko Araki, Masahito Abe, Hiroshi Ohta, Ryo Suzuki, Dai Nozawa
-
Publication number: 20150175541Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 29, 2013Publication date: June 25, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Tetsuo Takayama, Tsuyoshi Shibata, Fumiyasu Shiozawa, Kenichi Kawabe, Yuki Shimizu, Makoto Hamada, Akira Hiratate, Masato Takahashi, Fumihito Ushiyama, Takahiro Oi, Yoshihisa Shirasaki, Daisuke Matsuda, Chie Koizumi, Sota Kato
-
Publication number: 20150166523Abstract: A branched chain alkyl heteroaromatic ring derivative represented by formula (Ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of the orexin (OX) receptor antagonist activity.Type: ApplicationFiled: June 13, 2013Publication date: June 18, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Yuko Araki, Dai Nozawa, Ryo Suzuki, Hiroshi Ohta, Aya Futamura, Masahito Abe, Hideaki Amada, Kazuhide Konishi, Yuya Ogata
-
Patent number: 9045466Abstract: An amidine compound represented by formula (I) (wherein A1 represents a nitrogen atom or a group represented by formula CR6; A2 and A3 are the same as or different from each other and independently represent a nitrogen atom or a group represented by formula CH; R1 represents an aryl group which may be substituted by 1 to 5 substituents independently selected from a substituent group (2) or the like; R2 and R3 are the same as or different from each other and independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 haloalkyl group or a C1-6 alkoxy group; and R4 and R5 are the same as or different from each other and independently represent a hydrogen atom, a C1-6 haloalkyl group, a C1-6 alkyl group or the like) or a salt thereof. The compound is useful as an anti-fungal agent.Type: GrantFiled: July 27, 2012Date of Patent: June 2, 2015Assignees: TAISHO PHARMACEUTICAL CO., LTD, TOYAMA CHEMICAL CO., LTD.Inventors: Tetsuya Tanikawa, Yasunobu Ushiki, Fumihito Ushiyama, Toru Yamaguchi, Naoya Ono, Keiko Yamamoto, Risa Tsuruta, Yasuhiro Tsutsui, Noritomo Fujino, Ayumu Mori
-
Publication number: 20150141669Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 31, 2013Publication date: May 21, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
-
Patent number: 9035059Abstract: There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula —CR11R12—, —CO—, —CO—O—, or —CO—NH—, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.Type: GrantFiled: March 14, 2012Date of Patent: May 19, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tsuyoshi Busujima, Takahiro Oi, Hiroaki Tanaka, Yoshihisa Shirasaki, Kanako Iwakiri, Nagaaki Sato, Shigeru Tokita
-
Publication number: 20150045551Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia.Type: ApplicationFiled: March 29, 2013Publication date: February 12, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Shuhei Kashiwa, Takeshi Kuwada, Youichi Shimazaki
-
Publication number: 20150045553Abstract: Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds.Type: ApplicationFiled: December 27, 2012Publication date: February 12, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Toshio Nakamura, Seiji Masuda
-
Patent number: 8912192Abstract: Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.Type: GrantFiled: February 10, 2011Date of Patent: December 16, 2014Assignees: Taisho Pharmaceutical Co., Ltd, Nissan Chemical Industries, Ltd.Inventors: Noriyuki Hirasawa, Nobuyoshi Kamikido, Akihiko Tasaki, Shusei Ito
-
Patent number: 8894763Abstract: The present invention relates to a pigment composition containing a pigment and chondroitin sulfate or its salt, in which a content of chondroitin sulfate or its salt is equal to or larger than 0.1 part by weight (pbw) over 1 pbw of the pigment, and such pigment composition is available in the use for drug medicines and the like, and exhibits better dispersibility.Type: GrantFiled: March 14, 2011Date of Patent: November 25, 2014Assignee: Taisho Pharmaceutical Co., LtdInventors: Toshiki Nakajima, Masakiyo Urabe, Mariko Numao, Hiroki Tada, Kenji Yamabe
-
Publication number: 20140330010Abstract: Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, and depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds.Type: ApplicationFiled: December 7, 2012Publication date: November 6, 2014Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Toshio Nakamura, Seiji Masuda
-
Publication number: 20140275006Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth.Type: ApplicationFiled: October 25, 2012Publication date: September 18, 2014Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Mitsukane Yoshinaga, Takeshi Kuwada, Naoki Miyakoshi, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki
-
Patent number: 8822503Abstract: A 2-pyridone compound represented by the formula [1]: {wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.Type: GrantFiled: April 6, 2011Date of Patent: September 2, 2014Assignees: Taisho Pharmaceutical Co., Ltd, Nissan Chemical Industries, Ltd.Inventors: Takanori Kawaguchi, Kengo Watatani, Keiko Fusegi, Masahiro Bohno, Hajime Asanuma, Shoichi Kuroda, Yudai Imai, Tomomichi Chonan, Nagaaki Sato, Shigeru Tokita, Shigetada Sasako, Takumi Okada, Keishi Hayashi, Shin Itoh, Noriko Saito, Rui Jibiki, Seishi Ishiyama, Hirofumi Ota
-
Patent number: 8822674Abstract: A highly stable crystal of (1S)-1,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3,3-dimethyl-4-oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol, and a process for producing the crystal are provided. Specifically, an ethanolate having the following physical properties, and a plurality of other crystal forms transformed from the ethanolate are provided: (a) Having peaks at 2?=5.9 degrees, 17.1 degrees, 17.6 degrees and 21.5 degrees in X-ray powder diffraction (Cu—K?); (b) Showing characteristic absorption bands at 3538 cm?1, 3357 cm?1, 2964 cm?1, 1673 cm?1, 1634 cm?1 and 1505 cm?1 in an infrared absorption spectrum; and (c) Having a melting point in a vicinity of 111° C.Type: GrantFiled: August 19, 2011Date of Patent: September 2, 2014Assignee: Taisho Pharmaceutical Co., LtdInventors: Yoshihiro Kimura, Koreaki Imura, Naoto Osaki, Ayumi Matsushima
-
Publication number: 20140235577Abstract: To provide An external skin agent that prevents onset of atopic skin inflammations and is low irritant to skin, which is characterized by including: 1) clay modified by a compound having a quaternary amino group; and 2) a polymer or copolymer that has a side chain including a structure similar to a biological component.Type: ApplicationFiled: April 3, 2014Publication date: August 21, 2014Applicants: Taisho Pharmaceutical Co., Ltd., Pola Chemical Industries Inc.Inventors: Yasuhiro Ohara, Masashi SUZUKI, Norikazu Takano, Shunpei Mitsuyama
-
Publication number: 20140228377Abstract: A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (OX) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.Type: ApplicationFiled: July 4, 2012Publication date: August 14, 2014Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Masahito Abe, Aya Futamura, Ryo Suzuki, Dai Nozawa, Hiroshi Ohta, Yuko Araki
-
Patent number: 8796272Abstract: The present invention relates to novel compounds of formula [I] or pharmaceutically acceptable salts thereof: The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.Type: GrantFiled: February 21, 2012Date of Patent: August 5, 2014Assignee: Taisho Pharmaceutical Co., LtdInventors: Minoru Moriya, Hiroshi Ohta, Shuji Yamamoto, Kumi Abe, Yuko Araki, Xiang-Min Sun, Daisuke Wakasugi
-
Publication number: 20140155597Abstract: The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida, the genus Aspergillus and the genus Trichophyton and is useful as a medicinal agent.Type: ApplicationFiled: July 27, 2012Publication date: June 5, 2014Applicants: TOYAMA CHEMICAL CO., LTD., TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tetsuya Tanikawa, Yasunobu Ushiki, Fumihito Ushiyama, Toru Yamaguchi, Naoya Ono, Keiko Yamamoto, Risa Tsuruta, Yasuhiro Tsutsui, Noritomo Fujino, Ayumu Mori